Echo IQ partners with Mayo Clinic for AI study

Echo IQ (ASX:EIQ) announced a research collaboration with Mayo Clinic to evaluate its proprietary artificial intelligence platform in the rapidly growing cardio-oncology sector.

The upcoming study, based at Mayo Clinic Arizona and led by Dr Chadi Ayoub, will focus on assessing cardiac risk in oncology patients undergoing cancer therapies.

As global cancer survival rates continue to improve, managing the long-term, treatment-related cardiovascular complications—known as cardiotoxicity—has become a critical challenge for healthcare providers.

Echo IQ’s AI technology will process de-identified, routinely acquired echocardiographic data within a secure container environment to generate predictive risk scores for heart failure.

The primary clinical objective is to provide physicians with actionable risk stratification at the point of care, allowing for the early identification of at-risk patients before overt clinical symptoms emerge.

More than 20 million new cancer cases are diagnosed annually, creating a massive, high-need patient population that requires consistent cardiac monitoring during and after treatment.

Echo IQ’s CEO, Dustin Haines, highlighted that this partnership represents a pivotal opportunity to expand the application of their cardiac AI platform into a critical new clinical demographic where early detection can directly inform and improve treatment strategies.

The collaboration is expected to conclude in the first half of calendar year 2027, with both organisations intending to co-author a manuscript for peer-reviewed medical publication.